- After PROLONG trial results, the American College of Obstetricians and Gynecologists (ACOG) continues to endorse the use of weekly 17-hydroxyprogesterone caproate (17p) to reduce risk for spontaneous preterm birth.
Why this matters
- Preterm birth is a major cause of neonatal morbidity and mortality.
- The PROLONG trial demonstrated no difference in preterm birth composite index in women with weekly 17p vs placebo.
- Current ACOG guidelines will remain in effect.
- Additional planned meta-analyses and secondary analyses are needed to assess the effects of the intervention.
- ACOG reviews the results and implications of the PROLONG clinical trial, a randomized, double-blind clinical trial evaluating 17p injection (250 mg/mL) and its effects in reducing preterm birth and neonatal morbidity/mortality in patients with a history of a prior spontaneous singleton preterm delivery.
- Funding: None disclosed.
- ACOG will continue to monitor this topic, and recommendations may change with future research.